
## **Gilmar Reis**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4716187/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet Global Health, 2022, 10, e42-e51.	6.3	296
2	Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. The Lancet Regional Health Americas, 2022, 6, 100142.	2.6	17
3	Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2022, 106, 389-393.	1.4	1
4	Effect of Early Treatment with Ivermectin among Patients with Covid-19. New England Journal of Medicine, 2022, 386, 1721-1731.	27.0	142
5	Fluvoxamine for the treatment of COVID-19 – Author's reply. The Lancet Global Health, 2022, 10, e333.	6.3	4
6	Evaluating COVID-19 vaccines in the real world. Lancet, The, 2022, 399, 1205-1206.	13.7	7
7	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	8.6	19
8	Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19. JAMA Network Open, 2021, 4, e216468.	5.9	111
9	How COVID-19 has fundamentally changed clinical research in global health. The Lancet Global Health, 2021, 9, e711-e720.	6.3	122
10	Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial. Contemporary Clinical Trials, 2021, 107, 106466.	1.8	0
11	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 1919.	7.4	72
12	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	2.8	296
13	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	13.7	425
14	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care, 2020, 43, 2878-2881.	8.6	20
15	Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1364-1366.	1.4	23
16	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	11.4	207
17	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. American Journal of Medicine, 2019, 132, 1431-1440.e7.	1.5	8
18	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Ouality and Outcomes, 2019, 12, e005858.	2.2	17

GILMAR REIS

#	Article	IF	CITATIONS
19	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	13.7	155
20	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, 1177-1186.	2.8	49
21	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 2019, 140, 1578-1589.	1.6	34
22	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	2.2	45
23	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	13.7	1,625
24	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	13.7	394
25	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
26	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
27	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	2.8	131
28	Sharing best practices in applications of evidence-based medicine, problem-based learning and self-directed learning principles in medical training: A McMaster-Brazil collaboration workshop report. MedEdPublish, 2019, 8, .	0.3	0
29	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal, 2018, 39, 464-473.	2.2	28
30	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218.	13.7	426
31	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	13.7	651
32	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	27.0	2,211
33	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
34	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, 2018, 379, 1118-1127.	27.0	205
35	Incorporating evidence-based principles in medical training. Sharing experience with McMaster. MedEdPublish, 2018, 7, .	0.3	1
36	Cangrelor With and Without GlycoproteinÂllb/Illa Inhibitors inÂPatientsÂUndergoing PercutaneousÂCoronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	2.8	47

GILMAR REIS

#	Article	IF	CITATIONS
37	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	139
38	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation, 2017, 135, 1273-1275.	1.6	133
39	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	27.0	510
40	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AFâ€TIMI 48 Trial. Journal of the American Heart Association, 2017, 6, .	3.7	21
41	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. Stroke, 2016, 47, 2075-2082.	2.0	83
42	Cardioversion of Atrial Fibrillation in <scp>ENGAGE AF‶IMI</scp> 48. Clinical Cardiology, 2016, 39, 345-346.	1.8	53
43	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension, 2016, 68, 606-613.	2.7	21
44	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
45	Cause of Death and Predictors of All ause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association, 2016, 5, e002197.	3.7	127
46	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, The, 2015, 385, 2067-2076.	13.7	659
47	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 740-751.	3.9	218
48	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke, 2014, 45, 2372-2378.	2.0	46
49	A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia. Clinical Infectious Diseases, 2014, 59, 51-61.	5.8	184
50	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	27.0	2,261
51	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	27.0	4,215
52	Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT). International Journal of Cardiology, 2013, 168, 2416-2422.	1.7	10
53	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal, 2013, 34, 3117-3127.	2.2	53
54	Management of acute coronary syndromes in developing countries: ACute Coronary Events—a multinational Survey of current management Strategies. American Heart Journal, 2011, 162, 852-859.e22.	2.7	87

GILMAR REIS

#	Article	IF	CITATIONS
55	Ecocardiograma sob estresse com dobutamina em pacientes assintomáticos com regurgitação aórtica. Arquivos Brasileiros De Cardiologia, 2009, 93, 53-8.	0.8	0
56	Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 437.	7.4	581
57	Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis. Journal of the American College of Cardiology, 2004, 43, 393-401.	2.8	112
58	Risk factors for myocardial infarction in Brazil. American Heart Journal, 2003, 146, 331-338.	2.7	107
59	Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. American Journal of Cardiology, 1995, 75, 707-710.	1.6	113
60	A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. Gates Open Research, 0, 5, 117.	1.1	2
61	III Diretriz sobre tratamento do infarto agudo do miocárdio. Arquivos Brasileiros De Cardiologia, O, 83, 1-86.	0.8	24
62	A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the	1.1	9

TOGETHER master trial protocol. Gates Open Research, 0, 5, 117.